Compare Cassava Sciences Inc (FLNA) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $25.97 (market cap $115.44M). The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is far larger — about 2.9× Cassava Sciences Inc's market cap, and ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| FLNA | KOLD | |
|---|---|---|
Market Cap | $39.40M | $115.44M |
Volume | 759,018 | 6,626,046 |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $49.39 |
52-Week Low | $0.68 | $13.58 |
Typical Hold Time | 37 Days | 10 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
KOLD is trading at $24.84, down 5.8% over the past 24 hours amid bearish technical signals. The stock faces strong selling pressure with moving averages indicating a bearish trend and oscillators in neutral territory. Recent news highlights natural gas market volatility driven by record production levels and geopolitical tensions in the Middle East affecting energy commodities.
The outlook remains challenging with technical indicators pointing to continued downward pressure. Investment opportunities may emerge if the stock finds support near current levels, but risks include ongoing natural gas price volatility and geopolitical uncertainties. The bearish technical setup suggests cautious positioning is warranted until clearer fundamental catalysts emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
